Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Concurrent brimonidine 0.2% and 0.5% timolol · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution |
| 2 | ACTIVE_COMPARATOR | Concurrent Brimonidine 0.2% and 0.5% Timolol |
| Name | Type | Description |
|---|---|---|
| Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution | DRUG | Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening) |
| Concurrent brimonidine 0.2% and 0.5% timolol | DRUG | Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening) |
Inclusion Criteria: * Diagnosis of ocular hypertension or glaucoma * Patient requires IOP-lowering therapy in both eyes Exclusion Criteria: * Uncontrolled medical conditions * Contraindication to β-adrenoceptor antagonist therapy or brimonidine therapy
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
Concurrent brimonidine 0.2% and 0.5% timolol is used for the treatment of glaucoma. It is a small molecule therapy being developed by AbbVie Inc. for this ophthalmic condition. The drug is currently in Phase 3 clinical development.
The specific molecular target of Concurrent brimonidine 0.2% and 0.5% timolol is not specified. The drug combines brimonidine, an alpha-2 adrenergic receptor agonist, and timolol, a beta-blocker, which work together to lower intraocular pressure in patients with glaucoma.
Concurrent brimonidine 0.2% and 0.5% timolol is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV.
Concurrent brimonidine 0.2% and 0.5% timolol is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed.
Concurrent brimonidine 0.2% and 0.5% timolol was evaluated in a completed Phase 3 trial, NCT00651612, which enrolled 604 patients with glaucoma or ocular hypertension. The study was randomized, double-blind, and active-controlled, conducted in the United States with participants aged 18 years and older.